A5039511122- Breast Cancer Treatment Studies
- Estrogen and related hormone effects
- Advanced Breast Cancer Therapies
- Cancer Genomics and Diagnostics
- Lymphoma Diagnosis and Treatment
- Breast Lesions and Carcinomas
- Chronic Lymphocytic Leukemia Research
- Lung Cancer Treatments and Mutations
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Fibroblast Growth Factor Research
- Endometrial and Cervical Cancer Treatments
- Eosinophilic Disorders and Syndromes
- Breast Implant and Reconstruction
- Genetic factors in colorectal cancer
- Circular RNAs in diseases
- Kruppel-like factors research
- BRCA gene mutations in cancer
- Acute Myeloid Leukemia Research
- CNS Lymphoma Diagnosis and Treatment
- Statistical Methods in Clinical Trials
- Chronic Myeloid Leukemia Treatments
- Multiple Myeloma Research and Treatments
- Gene expression and cancer classification
- RNA modifications and cancer
- Cutaneous lymphoproliferative disorders research
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
2006-2025
European Institute of Oncology
2011-2023
Istituti di Ricovero e Cura a Carattere Scientifico
2005-2023
University of Milan
2005-2023
Ripamonti
2017
Ospedale San Paolo
2005-2007
Objective To compare the risk class attribution with molecular classification unknown to those known, according European Society of Gynaecological Oncology/European for Radiotherapy and Pathology (ESGO/ESTRO/ESP) 2020 guidelines on endometrial cancer, a focus group migration. Additionally, evaluate capability novel analysis algorithm reduce number required tests. Methods We conducted retrospective study including all consecutive patients cancer undergoing surgery comprehensive analyses...
We reviewed a large series of patients with essential thrombocythemia diagnosed on the basis Polycythemia Vera Study Group criteria, and reclassified them by evaluating their major morphologic features clinical course using World Health Organization classification. The review bone marrow biopsies 116 (44 males 72 females; aged 19 – 83 years, median 55 years; follow-up 121 months) led to 22 cases (19%) being classified as (ET), 24 (21%) chronic idiopathic myelofibrosis (CIMF)-0, 44 (37%)...
We examined microvessel density (MVD) and immunohistochemical expression of vascular endothelial growth factor (VEGF) in the bone marrow biopsy specimens 98 patients with Philadelphia chromosome-negative (Ph-) chronic myeloproliferative disorders (CMPDs). There were significantly more MVD "hot spots" idiopathic myelofibrosis (CIMF; mean +/- SD, 25.6 6.3) polycythemia vera (PV; 20.7 10.2) cases than essential thrombocythemia (ET) (10.1 4.5) normal control (NC) samples (7.5 3.6) (P < .05)....
The RET (REarranged during Transfection) receptor tyrosine kinase is targeted by oncogenic rearrangements in thyroid and lung adenocarcinoma. Recently, a (exon 12) rearrangement with FGFR1OP [fibroblast growth factor 1 (FGFR1) oncogene partner] was identified one chronic myelomonocytic leukemia (CMML) patient. We report the molecular cloning functional characterization of novel 11)‐RET 11) gene fusion event (named FGFR1OP‐RET), mediated reciprocal translocation t(6; 10)(q27; q11), patient...
We sought to characterise circulating and tissue tumour biomarkers of patients who developed early-stage non-small cell lung cancer (NSCLC) during long-term follow-up a chemoprevention trial (NCT00321893).Blood sputum samples were collected from 202 high-risk asymptomatic individuals with CT-detected stable nodules. Real-time PCR was performed on plasma quantify free DNA. Baseline serum investigated previously validated test based 13 miRNAs (miR-Test). Promoter methylation status p16,...
Background Molecular profiling of advanced non-small cell lung cancers (NSCLC) is essential to identify patients who may benefit from targeted treatments. In the last years, number potentially actionable molecular alterations has rapidly increased. Next-generation sequencing allows for analysis multiple genes simultaneously. Aims To evaluate feasibility and throughput next-generation in clinical diagnostics NSCLC. Methods A single-institution cohort 535 non-squamous NSCLC was profiled using...
<i>Background:</i> Lymphocyte-predominant Hodgkin disease (LPHD) differs in biology and clinical behaviour from classic disease. Almost 100% of LPHD neoplastic cells express CD20 thus rituximab could be effective; yet limited data are available. <i>Patients Methods:</i> We performed a retrospective analysis on patients with who were treated at our institution to determine the magnitude benefit offered by this drug. <i>Results:</i> Seven identified; 4...
Abstract Purpose: Women with hormone receptor–positive early breast cancers have a persistent risk of relapse and biomarkers for late recurrence are needed. We sought to identify tumor genomic aberrations associated increased late-recurrence risk. Experimental Design: In secondary analysis Study Letrozole Extension trial, case-cohort–like sampling selected 598 primary targeted next-generation sequencing gene mutations copy-number gains (CNGs). Correlations clinicopathologic factors distant...
The association of acute lymphoblastic leukaemia (ALL) and cystic fibrosis (CF) is rare. We present the case a paediatric patient affected by CF refractory B-cell precursor (BCP) ALL, who was treated with combined chimeric antigen receptor T-cells (CAR-T) allogeneic haematopoietic stem cell transplantation (HSCT).
Introduction: In patients with LARC, neoadjuvant CT-RT followed by curative surgery is the standard of care. Risk-adopted treatment based on MRI-predicting local T and N stage, radial margins vascular involvement while no molecular predictive markers are available. present prospective study, we investigated role serum ctDNA in LARC. Methods: Patients diagnosis LARC (T3-T4, N0 or any T, N+, M0) adenocarcinoma receiving capecitabine concomitant to 50,4 Gy after 8-10 weeks surgery, included. 18...